1. Home
  2. DBVT

DBVT

DBV Technologies S.A.

Logo DBV Technologies S.A.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 11:27am EST

$
-
.
-
-
-
$
-
.
-
-
-
.
-
-
%

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

Founded: 2002 Country:
France
France
Employees: N/A City: MONTROUGE
Market Cap: 130.8M IPO Year: N/A
Target Price: $7.00 AVG Volume (30 days): 53.2K
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.40 EPS Growth: N/A
52 Week Low/High: $0.65 - $2.37 Next Earning Date: 05-02-2024
Revenue: $15,728,000 Revenue Growth: 224.69%
Revenue Growth (this year): -41.58% Revenue Growth (next year): -70.60%

Share on Social Networks: